The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- Meiji Seika Pharma Seeks Japan Approval for Asenapine
May 29, 2015
- Otsuka Wins EU Approval for ADPKD Drug Jinarc
May 29, 2015
- Eisai Files Ultra-High Dose Mecobalamin for ALS in Japan
May 29, 2015
- Takeda Launches Once-Weekly DPP-4 Inhibitor Zafatek
May 29, 2015
- Sanofi Files NDA for Antiepileptic Treatment Vigabatrin
May 29, 2015
- Astellas Confident about Achieving FY2017 Japan Sales Target
May 28, 2015
- Asahi Kasei’s New Midterm Plan Aims to Maintain Profitability and Expand Sales in Healthcare Field
May 28, 2015
- Fycompa Receives Positive Opinion from CHMP for Adjunct Therapy for PGTC Seizures: Eisai
May 28, 2015
- Sanofi Oncology Business Unit Head Pascal Rigaudy to Become New President of Genzyme Japan
May 28, 2015
- Astellas’s New 3-Year Plan Targets Sales Growth in Mid-Single-Digit Range
May 27, 2015
- GSK’s Aldreb Debuts as Last Resort for Multidrug Resistant Pseudomonas Aeruginosa Infection
May 26, 2015
- Masanobu Suzuki Tapped as President of Nippon Kayaku
May 26, 2015
- Chugai Files NDA for Combination Psoriasis Vulgaris Drug
May 26, 2015
- Celgene Launches Multiple Myeloma Treatment Pomalyst; Keio Professor Acknowledges Its Efficacy in PFS, OS Improvement
May 26, 2015
- Sales Increase 19.3% for 3 Generic-Only Makers; Incentive for DPC Hospitals Spurs Growth
May 25, 2015
- Ken Masuo to Become Japan Representative for Oncology Business: AZ
May 25, 2015
- Blopress AG Share Tops 60% in Generic Market, Aims for Further Growth: ASKA President Yamaguchi
May 25, 2015
- 180 Billion Yen Sales in FY2017 Is “Quite Reachable”: Meiji Seika Pharma President
May 22, 2015
- Oncologics Retain Top Position in Therapeutic Category Sales Ranking in FY2014: IMS
May 22, 2015
- Japan Pharma Market Down by 0.6% to Under 10 Trillion Yen in FY2014: IMS
May 22, 2015
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…